Study | Patient Population | Treatment (N) | CR (n; %) | PR (n; %) | OR (n; %) | Criteria |
---|---|---|---|---|---|---|
Czuczman et al [4]: Prospective; Single treatment group; Intent to treat trial | N-40; 18 years and older with CD 20+ follicular lymphoma | R-CHOP N = 40 | 22; 55% | 16; 40% | 38; 95% | Table 1 |
Hiddemann W et al. [5]: Prospective, randomized, non-crossover, open label multicenter phase 3 trial | N = 428; 18 years and older with untreated advanced stage follicular lymphoma | R-CHOP (N = 223) vs. CHOP (N = 205) | 44; 20% 35; 17% | 170; 77% 150; 73% | 214; 96% 185; 90% | IWG[13] |
Domingo-Domenech et al. [6]: Prospective, non-randomized, non-crossover, open label multicenter phase 2 trial | N = 16; 18 to 70 years age with CD 20+ follicular lymphoma | R-CHOP (N = 16) | 12; 75% | 2; 13% | 14; 88% | IWG [13] |
Marcus R et al. [7]: Prospective, randomized, non-crossover trial | N = 321; 18 years or older, untreated CD 20+ follicular lymphoma | R-CVP (N = 162) vs. CVP (N = 159) | 66; 41% 16; 11% | 65; 40% 74; 47% | 131; 81% 90; 57% | IWG[13] |